Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial. Harding, J. J., Piha-Paul, S., Shah, R. H., Cleary, J. M., Quinn, D. I., Brana, I., Moreno, V., Borad, M. J., Loi, S., Spanggaard, I., Ford, J. M., DiPrimeo, D., Berger, M. F., Eli, L., Meric-Bernstam, F., Solit, D. B., Abou-Alfa, G. K. LIPPINCOTT WILLIAMS & WILKINS. 2022
View details for Web of Science ID 000863680301245